Rapid Micro Biosystems, Inc., a life sciences technology company, reported that Samsung Biologics has selected its Growth Direct platform to automate its microbial quality control processes to deliver increased efficiency, more robust data integrity, and scalable quality control operations.

“Samsung Biologics is a leading global contract development and manufacturing organization (CDMO) and has demonstrated an unwavering commitment to automation and quality management in biopharmaceutical manufacturing,” said Robert Spignesi, President, and CEO of Rapid Micro Biosystems. “The Growth Direct improves operational efficiency and data integrity in the quality control microbiology lab, and we are proud to partner with Samsung Biologics.”

According to Rapid Micro Biosystems, Growth Direct is the only fully automated, non-destructive growth-based platform for microbiology quality control testing that offers faster time to results, improved data integrity, and enhanced accuracy, with greater sample capacity.